李敏 首席投资官

李敏博士任蓝海资本首席投资官,具有丰富的医学科研和医药医疗投资管理经验。李敏博士拥有30余载国内、外医药研究经验。曾在中国预防医学科学院、首都儿科研究所、北京大学医学部、法国国家科研中心等科研院所工作。在生物科技、医药健康领域特别是药物筛选研究方面具有丰富经验,主持和参加了多项研究课题,在国内外刊物上发表了大量研究论文与综述,并与政府主管部门、国内外企业、研究机构和行业协会建立了广泛联系。

李敏博士曾任建银国际医疗产业基金总经理,参与了国内第一支专注于医疗健康产业股权投资的医疗基金--建银医疗基金的募集创立及投资管理工作。

李敏博士是中国药理学会会员、中国药学会高级会员,并曾担任多家中、英文学术期刊的编委和特约审稿人、国家科委国际科技合作重点项目计划评审专家。 李敏博士拥有同济医科大学医学学士、中国预防医学科学院免疫学硕士、法国图卢兹第三大学细胞与分子药理学专业博士学位。

Min Li, Ph.D
Chief Investment Officer

Dr. Li is a Chief Investment Officer of Blue Ocean Capital. She has extensive experience in medical research and healthcare investment management with more than 30 years’ experience in pharmaceutical research in China and abroad. She used to work at scientific research institutions including Chinese Center for Disease Control and Prevention, Capital Institute of Pediatrics, Peking University Health Science Center and the French National Center for Scientific Research. Dr. Li has a wealth of experience in the biotechnology and healthcare sectors, especially the study of drug screening. She has presided over and participated in a number of research topics, has published a lot of research papers and review articles in Chinese and international journals and has built extensive networks with governmental authorities, domestic and foreign enterprises, research institutes and industry associations.

Dr. Li used to be the General Manager of CCBI Healthcare Fund , participated in the fund raising and investment management of the fund.

Dr. Li is a member of Chinese Pharmacological Society and a senior member of Chinese Pharmaceutical Association. She served as an editorial board member and a special reviewer for several Chinese and English academic journals. She was also a planning and review expert for key projects of international scientific and technological cooperation initiatives of the State Scientific and Technological Commission of China. Dr. Li holds a bachelor’s degree in medicine from Tongji Medical College of HUST, a master’s degree in immunology from Chinese Center for Disease Control and Prevention, and a doctor’s degree in cellular and molecular pharmacology from Université Toulouse III – Paul Sabatier.